Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Q3 FY2022 Earnings Presentation
26 slides from Valiant Organics's earnings presentation, Feb 8, 2022
Slide 1: Valiant Organics Investor Presentation Filing Letter
•••• Valiant Organics Limited · Date: February 08, 2022 To, To, Listing/Compliance Department Listing/Compliance Department BSELTD National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, "Exchange Plaza",Plot No.C/1, Mumbai- 400 001. G Block Bandra-Kurla Complex, Bandra (E)
Slide 2: Earnings Presentation | Q3 / 9M - FY22
Earnings Presentation | Q3 / 9M - FY22
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisdine and Para Anisidne Diversified client base across Amongst 1st few
Slide 4: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 5: Chemistries And Product Basket
Chemistries And Product Basket Chlorination Hydrogenation Key Products: Industries Served: Key Products: Industries Served: • Para ChloroPhenol (PCP) • Agro Chemicals • Ortho Anisidine • Dyes • Ortho ChloroPhenol (OCP) • Cosmetics • Para Anisidine • Pigments • 2,4 Di Chlorophenol (2,4 DCP) • Veterin
Slide 6: Manufacturing Footprint
MANUFACTURING FOOTPRINT CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 1,500 TPM JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 2,250 TPM 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 • Capa
Slide 7: Key Strengths
Key Strengths Domain expertise and broad process Plant locations are understanding in a variety strategically located near of chemistries. The Wide supply chain ports to provide a executive team is made up provides the continuous competitive advantage, of first-generation availability of adequate si
Slide 8: Capex Projects
Capex Projects Approx Capex Product Installed Capacity Project Status Remarks (INR Mn) Commissioned Para Nitro Aniline (PNA) & Completing phase-wise • Expansion from 550 TPM to 750 TPM at Vapi plant Ortho Chloro Para Nitro 550 ~ 70 • Full capacity addition in progress Aniline (OCPNA) Ortho Nitro Ani
Slide 9: Q3/9M-FY22 Highlights
Q3/9M-FY22 HIGHLIGHTS Valiant Organics Limited | January 2022 8
Slide 10: Quarterly and YTD Financial Highlights
QUARTERLY AND YTD FINANCIAL HIGHLIGHTS Q3-FY22 Financial Highlights 9M-FY22 Financial Highlights INR 2,884 Mn INR 8,056 Mn Operational Revenue Operational Revenue INR 502 Mn INR 1,478 Mn Operating EBITDA Operating EBITDA 17.41% 18.35% Operating EBITDA Margin Operating EBITDA Margin INR 322 Mn INR 90
Slide 11: Q3-FY22 Operational Highlights
Q3-FY22 Operational Highlights • YoY Sales growth driven by healthy demand environment and contribution from new product additions like PAP and Para Anisidine which have started contributing to the top line in this year. • The PAP plant is still under ramp up stage and will gradually increase contri
Slide 12: Standalone Revenues - Key Chemistries
Standalone Revenues - Key Chemistries Chlorination (INR Mn) Hydrogenation (INR Mn) Ammonalisation (INR Mn) Other (INR Mn) 1000 916 764 900 800 730 900 QUARTERLY 800 800 700 700 539 700 471 199 600 600 600 500 500 400 500 189 400 400 400 300 300 300 200 200 200 100 100 100 0 0 0 Q3-FY21 Q3-FY22 Q3-FY
Slide 13: Volumes – Key Chemistries
Volumes – Key Chemistries Chlorination (MT) Hydrogenation (MT) Ammonalisation (MT) Other (MT) 5,610 4,363 6, 000 4, 400 4,439 3,307 3, 400 4, 350 5, 000 QUARTERLY 4, 300 3, 300 4, 000 4, 250 543 3, 200 4, 200 3, 000 600 4, 150 4,063 3, 100 500 4, 100 2,977 220 2, 000 400 3, 000 4, 050 300 4, 000 200
Slide 14: Quarterly Consolidated Financial Performance
Quarterly Consolidated Financial Performance Particulars (INR Mn) Q3-FY22 Q3-FY21 Y-O-Y Q2-FY22 Q-O-Q Revenue from Operations 2,884 2,066 39.6% 2,732 5.6% Total Expenses 2,382 1,549 53.8% 2,259 5.4% EBITDA 502 517 (2.9)% 473 6.1% EBITDA Margin (%) 17.41% 25.02% (761) Bps 17.31% 10 Bps Other Income 2
Slide 15: YTD Consolidated Financial Performance
YTD Consolidated Financial Performance Particulars (INR Mn) 9M-FY22 9M-FY21 Y-O-Y Revenue from Operations 8,056 5,208 54.7% Total Expenses 6,578 3,739 75.9% EBITDA 1,478 1,469 0.6% EBITDA Margin (%) 18.35% 28.21% (986) Bps Other Income 52 45 15.6% Depreciation 212 155 36.8% Finance Cost 48 36 33.3%
Slide 16: Quarterly Standalone Financial Performance
Quarterly Standalone Financial Performance Particulars (INR Mn) Q3-FY22 Q3-FY21 Y-O-Y Q2-FY22 Q-O-Q Revenue from Operations 2,608 1,600 63.0% 2,127 22.6% Total Expenses 2,162 1,168 85.1% 1,760 22.8% EBITDA 446 432 3.2% 367 21.5% EBITDA Margin (%) 17.10% 27.00% (990) Bps 17.25% (15) Bps Other Income
Slide 17: YTD Standalone Financial Performance
YTD Standalone Financial Performance Particulars (INR Mn) 9M-FY22 9M-FY21 Y-O-Y Revenue from Operations 6,579 4,040 62.8% Total Expenses 5,373 2,833 89.6% EBITDA 1,206 1,207 (0.1)% EBITDA Margin (%) 18.33% 29.88% NA Other Income 46 92 (50.0)% Depreciation 200 137 46.0% Finance Cost 46 23 NA PBT 1,00
Slide 18: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW Valiant Organics Limited | January 2022 17
Slide 19: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY19 FY20 FY21* 9M-FY22* Operational Income 6,923 6,749 7,548 8,056 Total Expenses 5,125 4,946 5,496 6,578 EBITDA 1,798 1,803 2,052 1,478 EBITDA Margin 25.97% 26.71% 27.19% 18.35% Other Income 87 63 59 48 Depreciation 136 158 212 52 Finan
Slide 20: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (INR Mn) FY20 FY21* H1-FY22* Particulars (INR Mn) FY20 FY21* H1-FY22* EQUITY 4,007 5,086 5,603 Non-Current Assets 4,451 5,729 6,327 a) Equity Share Capital 121 272 272 a) Property, Plant and Equipment 2,729 4,967 5,094 b) Other Equity 3,736 4,747 5,253 b) Capit
Slide 21: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY19 FY20 FY21* 9M-FY22* Revenue from Operations 6,060 5,836 5,742 6,579 Total Expenses 4,283 4,103 4,170 5,373 EBITDA 1,777 1,733 1,572 1,206 EBITDA Margin 29.32% 29.69% 27.37% 18.33% Depreciation 118 130 186 46 Finance Cost 15 10 35 200 O
Slide 22: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY20 FY21* H1-FY22* Particulars (INR Mn) FY20 FY21* H1-FY22* EQUITY 3,875 5,023 5,488 Non-Current Assets 4,381 5,797 6,506 a) Equity Share Capital 121 272 272 a) Property, Plant and Equipment 2,525 4,771 4,901 b) Capital Work In Progress 1,291 459 932 b)
Slide 23: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 8, 500 2,300 80.00% 1, 500 1,332 80. 00% 2,052 1,282 1,309 8,056 70.00% 70. 00% 8, 000 2,000 1,798 1,803 1, 200 60.00% 60. 00% 7,548 1,700 908 7, 500 1,478 50.00% 900 50
Slide 24: Capital Market Information
Capital Market Information Share Price as of 31st December, 2021 40% 20% 0% -20% -40% Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 VALIANT Sensex Price Data (31st December, 2021) INR Shareholding pattern as of 31st December, 2021 Face Value 10.00 Market Price 1
Slide 25: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 26: Thank You
THANK YOU Valiant Organics Limited | January 2022 25